Cargando…

TIC10/ONC201: a bend in the road to clinical development

Detalles Bibliográficos
Autores principales:	Greer, Yoshimi Endo, Lipkowitz, Stanley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381697/ https://www.ncbi.nlm.nih.gov/pubmed/25859547

Ejemplares similares

ONC201 kills breast cancer cells in vitro by targeting mitochondria
por: Greer, Yoshimi Endo, et al.
Publicado: (2018)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
por: Farmaki, Elena, et al.
Publicado: (2023)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
por: Dwucet, Annika, et al.
Publicado: (2021)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
por: Kundu, Manjari, et al.
Publicado: (2022)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor()
por: Hayes-Jordan, Andrea A., et al.
Publicado: (2018)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
por: Lim, Bora, et al.
Publicado: (2019)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer
por: Wedam, Rohan, et al.
Publicado: (2023)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
por: Graves, Paul R., et al.
Publicado: (2019)

PEDT-18 PHASE I/II TRIAL OF OP-10 (ONC201) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE MIDLINE GLIOMA
por: Okada, Keiko, et al.
Publicado: (2022)

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
por: Yuan, Xun, et al.
Publicado: (2017)

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells
por: Amoroso, Francesca, et al.
Publicado: (2021)

Molecular Mechanisms Involved in the Chemical Instability of ONC201 and Methods to Counter Its Degradation in Solution
por: Annereau, Maxime, et al.
Publicado: (2023)

European clinical guidelines for Tourette Syndrome and other tic disorders
por: Roessner, Veit, et al.
Publicado: (2011)

Correction to “Mitochondrial Protease ClpP Is a Target for the Anticancer Compounds ONC201 and Related Analogues”
por: Graves, Paul R., et al.
Publicado: (2022)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

MEDB-46. ONC201 affects Group 3 Medulloblastoma growth by impairing cancer stem cells
por: Abballe, Luana, et al.
Publicado: (2022)

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
por: Jackson, Evangeline R., et al.
Publicado: (2023)

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
por: Greer, Yoshimi Endo, et al.
Publicado: (2019)

Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study
por: Feng, Yuan, et al.
Publicado: (2016)

Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure–Activity Relationships
por: Bárány, Péter, et al.
Publicado: (2018)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Frictions with Ice in Tic Douleureux
Publicado: (1872)

Heterogenesis Once More
Publicado: (1904)

Vivisection Once More
Publicado: (1881)

Cannot write session to /tmp/vufind_sessions/sess_k01st470js8laki8hun5k2v47a